Phase 3 bridging study of bempedoic acid / ezetimibe combination pill in the patients with hypercholesterolaemia

Trial Profile

Phase 3 bridging study of bempedoic acid / ezetimibe combination pill in the patients with hypercholesterolaemia

Planning
Phase of Trial: Phase III

Latest Information Update: 05 Jul 2017

At a glance

  • Drugs Bempedoic acid/ezetimibe (Primary)
  • Indications Hypercholesterolaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Jul 2017 According to an Esperion Therapeutics media release, additional design details for this study will be provided upon initiation by the fourth quarter of 2017, with top-line results expected by the end of 2018.
    • 05 Jul 2017 New trial record
    • 26 Jun 2017 According to an Esperion Therapeutics media release, the U.S. Food and Drug Administration (FDA) recently confirmed the regulatory pathway to approval for the once-daily, oral combination pill of bempedoic acid 180 mg and ezetimibe 10 mg.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top